No Evidence Allowed: The Law That Banned Its Own Proof

By Alex Martinez

Here is a fact that should bother you regardless of how you feel about cannabis: the federal agency responsible for deciding whether marijuana has medical value is the same agency that makes it nearly impossible to conduct the research needed to find out. That is not an accident. That is the architecture.

And after fifty years, that architecture just cracked open, slightly, partially, and only after powerful forces spent decades making sure it wouldn’t. In 1970, Congress placed cannabis in Schedule I of the Controlled Substances Act—falling into the most restrictive classification, reserved for substances with “no currently accepted medical use” and high abuse potential. Heroin sits in Schedule I. So did cannabis, until very recently.

Schedule I status is not just a label. It is a legal mechanism. Under the CSA, the DEA cannot reschedule cannabis without a determination from the Department of Health and Human services that the plant has an accepted medical use. And that determination requires clinical evidence. Rigorous, federally sanctioned, peer-reviewed evidence. The same Schedule I classification makes that evidence nearly impossible to produce.

To study a Schedule I substance, a researcher must obtain a special DEA license—a separate, more burdensome process than what’s required for schedule II though V substances. They must navigate approvals from multiple federal and state agencies before they can even apply. In California, all trials involving Schedule I substances must be registered with a special state Research Advisory Panel. Once approvals are secure, researchers must track every microgram of material, maintain DEA-mandated security measures, and work within annual production quotas that limit how much cannabis can even be manufactured for research purposes. For decades, virtually all research cannabis in the United States came from a single farm at the University of Mississippi, widely criticized for producing material that differed heavily to what Americans were actually consuming.

The result: the DEA remains powerless to reschedule marijuana without evidence, and the Schedule I status put cannabis in a Mission Impossible movie. This is not a new problem. The first petition to reschedule cannabis was filed in 1972—just two years after the CSA was enacted. It was denied in 1994, after 22 years of legal challenges. A second petition took seven years to review. A third was denied nine years after it was filed. A petition filed in 2013 by two sitting state governors remained pending for over a decade. More than fifty years of asking, the loop held.

It would be easy to frame this as an abstract policy dispute, a bureaucratic curiosity. It is not. Six in ten Americans used marijuana in the last year, many for pain, sleep, or anxiety—conditions where cannabis may offer real benefit and where interactions with other medications are poorly understood. Their doctors could not give them adequate guidance because adequate guidance did not exist. The research was never allowed to happen.

The layering of bureaucracy reportedly discouraged researchers from even applying for grant funding. The field was quietly hollowed out, not by a lack of interest, but by a system that made the work so costly, so slow, and so legally fraught that many scientists chose other subjects. Even people who oppose marijuana legalization broadly agree that more research is needed. That near-universal consensus existed for decades. It was not enough to break the loop.

It is worth sitting with the intentionality of this structure: Schedule I was not designed as a temporary holding category pending further study. It was designed as a terminus. A substance places there is defined, by law, as having no medical use, which then becomes the justification for preventing the studies that might prove otherwise. The classification did not just restrict access to cannabis, it restricted access to knowledge about cannabis (a heinous crime, if you ask me). The DEA spent over fifty years demanding evidence it had structurally prevented anyone from gathering. That is not regulatory caution. That is regulatory capture of the scientific process itself—a feedback loop dressed up as due diligence.

On April 23, 2026, the DOJ issued a final order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III—a classification that carries meaningfully lower research barriers and, for the first time in federal law, formally acknowledged that cannabis has accepted medical use. Read that again. After fifty years of the DEA insisting it could not reschedule cannabis because there was insufficient evidence on medicinal use, the government quietly conceded the point using evidence gathered largely from state medical programs it had no role in creating and spent decades trying to suppress.

The loop did not break because the system worked. It cracked because the states went around it. This crack is narrow, recreational cannabis and most bulk marijuana remain Schedule I. The broader rescheduling of all cannabis is now subject to an expedited administrative hearing beginning June 29, 2026—with forces trying to seal the crack already mobilizing. Anti- rescheduling groups have filed suit. A House Appropriations bill contains language barring the DOJ from using funds to complete the rescheduling. Powerful congressional voices have made their position clear. The argument they are making, stripped of its political framing, is the same one the DEA made for fifty years: we don’t have enough evidence. What they do not say—what they have never said—is who made sure of that.

No evidence allowed. By design. And some would like to keep it that way.